Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.
Two spectrophotometric methods are presented for the simultaneous determination of ezetimibe/simvastatin and ezetimibe/atorvastatin binary mixtures in combined pharmaceutical dosage forms without prior separation. The first is the derivative ratio method where the amplitudes of the first derivative of the ratio spectra ((1) DD) at 299.5 and 242.5 nm were found to be linear with ezetimibe and simvastatin concentrations in the ranges 0.5-20 µgml(-1) and 1-40 µgml(-1) , respectively, whereas the amplitudes of the first derivative of the ratio spectra ((1) DD) at 289.5 and 288 nm were selected to determine ezetimibe and atorvastatin in the concentration ranges 5-50 µgml(-1) and 1-40 µgml(-1) , respectively. The second is the H-point standard additions method; absorbances at the two pairs of wavelengths, 228 and 242 nm or 238 and 248 nm, were monitored while adding standard solutions of ezetimibe or simvastatin, respectively. For the analysis of ezetimibe/atorvastatin mixture, absorbance values at 226 and 248 nm or 212 and 272 nm were monitored while adding standard solutions of ezetimibe or atorvastatin, respectively. Moreover, differential spectrophotometry was applied for the determination of ezetimibe in the two mixtures without any interference from the co-existing drug. This was performed by measurement of the difference absorptivities (ΔA) of ezetimibe in 0.07 M 30% methanolic NaOH relative to that of an equimolar solution in 0.07 M 30% methanolic HCl at 246 nm. The described methods are simple, rapid, precise and accurate for the determination of these combinations in synthetic mixtures and dosage forms.
Maher
Hadir M
HM
Faculty of Pharmacy, Department of Pharmaceutical Analytical Chemistry, University of Alexandria, El-Messalah, Alexandria 21521, Egypt. hadirrona@yahoo.com
Youssef
Rasha M
RM
Hassan
Ekram M
EM
El-Kimary
Eman I
EI
Barary
Magda A
MA
D000069059:Atorvastatin; D001384:Azetidines / Q000032:analysis*; D002138:Calibration; D004338:Drug Combinations; D004339:Drug Compounding; D004355:Drug Stability; D000069438:Ezetimibe; D000069499:Ezetimibe, Simvastatin Drug Combination; D006538:Heptanoic Acids / Q000032:analysis*; D000960:Hypolipidemic Agents / Q000032:analysis*; D015394:Molecular Structure; D011758:Pyrroles / Q000032:analysis*; D015203:Reproducibility of Results; D019821:Simvastatin / Q000032:analysis*; D012997:Solvents / Q000737:chemistry; D013056:Spectrophotometry, Ultraviolet / Q000379:methods; D013607:Tablets / Q000737:chemistry
D001384:Azetidines; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D012997:Solvents; D013607:Tablets; D000069059:Atorvastatin; D019821:Simvastatin; D000069438:Ezetimibe